• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

    10/13/22 4:18:01 PM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email
    SC 13D/A 1 d391908dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

    (Amendment No. 4)*

     

     

    EARGO, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    270087109

    (CUSIP number)

    Edwin de Graaf

    Cooperatieve Gilde Healthcare V U.A.

    Newtonlaan 91

    3584 BP Utrecht

    The Netherlands

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 11, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 270087109    13D    Page 1 of 7 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Cooperatieve Gilde Healthcare V U.A.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      WC

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,869,290 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,869,290 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,869,290 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.75% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    All shares are held of record by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Gilde Healthcare V Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 39,385,438 shares of common stock outstanding of Eargo, Inc. (the “Issuer”) as of August 3, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022.


    CUSIP NO. 270087109    13D    Page 2 of 7 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Gilde Healthcare V Management B.V.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,869,290 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,869,290 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,869,290 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.75% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    All shares are held of record by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Gilde Healthcare V Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 39,385,438 shares of common stock outstanding of Eargo, Inc. (the “Issuer”) as of August 3, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022.


    CUSIP NO. 270087109    13D    Page 3 of 7 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Gilde Healthcare Holding B.V.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,869,290 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,869,290 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,869,290 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.75% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    All shares are held of record by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Gilde Healthcare V Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 39,385,438 shares of common stock outstanding of Eargo, Inc. (the “Issuer”) as of August 3, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022.


    CUSIP NO. 270087109    13D    Page 4 of 7 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Manapouri B.V. (100% owned by Edwin de Graaf)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,869,290 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,869,290 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,869,290 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.75% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    All shares are held of record by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Gilde Healthcare V Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 39,385,438 shares of common stock outstanding of Eargo, Inc. (the “Issuer”) as of August 3, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022.


    CUSIP NO. 270087109    13D    Page 5 of 7 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Martemanshurk BV (100% owned by Pieter van der Meer)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,869,290 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,869,290 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,869,290 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.75% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    All shares are held of record by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Gilde Healthcare V Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare V Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 39,385,438 shares of common stock outstanding of Eargo, Inc. (the “Issuer”) as of August 3, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022.


    CUSIP NO. 270087109    13D    Page 6 of 7 Pages

     

    This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D amends the initial Statement on Schedule 13D filed on October 30, 2020 (as so amended, the “Schedule 13D”), relating to the common stock, par value $0.0001 per share (“Common Stock”), of Eargo, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 4 reflects, among other things, the sales of shares of Common Stock by Cooperatieve Gilde Healthcare V U.A. (“Gilde Healthcare”). Capitalized terms used but not defined in this Amendment No. 4 shall have the same meanings ascribed to them in the Schedule 13D.

    Item 1. Security and Issuer.

    There are no changes to the Item 1 information previously filed.

    Item 2. Identity and Background.

    There are no changes to the Item 2 information previously filed.

    Item 3. Source and Amount of Funds or Other Consideration.

    There are no changes to the Item 3 information previously filed.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

    Between October 7, 2022 and October 11, 2022, Gilde Healthcare sold an aggregate of 250,000 shares of Common Stock of the Company in open market transactions.

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated in its entirety below:

    (a) According to the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022, there were 39,385,438 shares of Common Stock outstanding as of August 3, 2022.

    Gilde Healthcare is the record holder of an aggregate of 1,869,290 shares of Common Stock, which represents beneficial ownership of approximately 4.75% of the outstanding shares of Common Stock as of August 3, 2022.

    GHCVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare.

    As a result, each of the Reporting Persons may beneficially own 1,869,290 shares of Common Stock, or approximately 4.75% of the outstanding Common Stock.

    (b) Each Reporting Person has shared power to vote and dispose of 1,869,290 shares of Common Stock.

    (c) Except as reported on Annex A, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

    (d) Only Gilde Healthcare has the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by Gilde Healthcare.

    (e) As a result of the transactions described herein, the Reporting Persons ceased to be the beneficial owner of more than 5% of the Issuer’s outstanding Common Stock. The filing of this Amendment No. 4 represents the final amendment to this Schedule 13D and constitutes an exit filing for the Reporting Persons.


    CUSIP NO. 270087109    13D    Page 7 of 7 Pages

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer.

    Except as referenced herein, there are no changes to the Item 6 information previously filed.

    Item 7. Materials to be Filed as Exhibits.

    There are no changes to the Item 7 information previously filed.

    Signatures

    After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

     

    Dated: October 13, 2022     COOPERATIEVE GILDE HEALTHCARE V U.A.
        By: GILDE HEALTHCARE V MANAGEMENT BV
        Its: Manager
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        GILDE HEALTHCARE V MANAGEMENT B.V.
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        GILDE HEALTHCARE HOLDING B.V.
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        MANAPOURI B.V.
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        MARTEMANSHURK B.V.
        By:  

    /s/ Pieter van der Meer

        Name:   Pieter van der Meer
        Title:   Managing Director


    Annex A

    60 Day Trading History

    The following transactions were effected by Cooperatieve Gilde Healthcare V U.A. in Common Stock during the past 60 days:

     

    Trade Date

       Amount Sold      Weighted Average
    Price Per Share
     

    10/04/2022

         197,973      $ 1.098  

    10/05/2022

         37,801      $ 1.025  

    10/06/2022

         641,622      $ 1.101  

    10/07/2022

         26,243      $ 0.896  

    10/10/2022

         46,376      $ 0.705  

    10/11/2022

         177,381      $ 0.691  
    Get the next $EAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    Financials

    Live finance-specific insights

    See more
    • Eargo Reports Second Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

      8/10/23 4:05:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Reports First Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

      5/11/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

      SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

      5/4/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eargo downgraded by William Blair

      William Blair downgraded Eargo from Outperform to Mkt Perform

      9/23/21 7:17:15 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by JP Morgan with a new price target

      JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

      9/23/21 5:05:21 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

      9/23/21 5:03:59 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Eargo Appoints Katie Bayne to Board of Directors

      SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

      6/10/21 4:30:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

      SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

      1/31/24 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

      SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

      11/1/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

      SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

      10/26/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eargo Inc.

      15-12G - Eargo, Inc. (0001719395) (Filer)

      2/26/24 1:39:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:18 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:16 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:03:54 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Narula Onkarr

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:01:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 5:59:27 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      2/16/24 11:30:56 AM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      10/30/23 5:21:26 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

      SC 13G/A - Eargo, Inc. (0001719395) (Subject)

      1/6/23 11:49:44 AM ET
      $EAR
      Medical Specialities
      Health Care